$3.34
RAPT Therapeutics is a biotechnology business based in the US. RAPT Therapeutics shares (RAPT) are listed on the NASDAQ and all prices are listed in US Dollars. RAPT Therapeutics employs 126 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy RAPT Therapeutics stock
How to buy RAPT Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – RAPT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy RAPT Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
RAPT Therapeutics stock price (NASDAQ: RAPT)
Use our graph to track the performance of RAPT stocks over time.RAPT Therapeutics shares at a glance
Latest market close | $3.12 |
---|---|
52-week range | $2.61 - $27.35 |
50-day moving average | $3.60 |
200-day moving average | $12.15 |
Wall St. target price | $14.83 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-3.08 |
Is it a good time to buy RAPT Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
RAPT Therapeutics price performance over time
Historical closes compared with the close of $3.12 from 2024-07-25
1 week (2024-07-19) | -5.17% |
---|---|
1 month (2024-06-27) | 7.96% |
3 months (2024-04-26) | -61.48% |
6 months (2024-01-26) | -87.66% |
1 year (2023-07-27) | -86.17% |
---|---|
2 years (2022-07-27) | -85.66% |
3 years (2021-07-27) | 30.91 |
5 years (2019-07-23) | N/A |
RAPT Therapeutics financials
Gross profit TTM | $1.5 million |
---|---|
Return on assets TTM | -39.6% |
Return on equity TTM | -67.21% |
Profit margin | 0% |
Book value | $3.76 |
Market Capitalization | $114.8 million |
TTM: trailing 12 months
RAPT Therapeutics share dividends
We're not expecting RAPT Therapeutics to pay a dividend over the next 12 months.
RAPT Therapeutics share price volatility
Over the last 12 months, RAPT Therapeutics's shares have ranged in value from as little as $2.61 up to $27.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while RAPT Therapeutics's is 0.358. This would suggest that RAPT Therapeutics's shares are less volatile than average (for this exchange).
RAPT Therapeutics overview
RAPT Therapeutics, Inc. , a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.
Frequently asked questions
What percentage of RAPT Therapeutics is owned by insiders or institutions?Currently 1.846% of RAPT Therapeutics shares are held by insiders and 92.894% by institutions. How many people work for RAPT Therapeutics?
Latest data suggests 126 work at RAPT Therapeutics. When does the fiscal year end for RAPT Therapeutics?
RAPT Therapeutics's fiscal year ends in December. Where is RAPT Therapeutics based?
RAPT Therapeutics's address is: 561 Eccles Avenue, South San Francisco, CA, United States, 94080 What is RAPT Therapeutics's ISIN number?
RAPT Therapeutics's international securities identification number is: US75382E1091 What is RAPT Therapeutics's CUSIP number?
RAPT Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75382E109
More guides on Finder
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question